Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients.

Background: Information regarding coronavirus disease 2019 (COVID-19) in haemodialysis (HD) patients is limited and early studies suggest a poor outcome. We aimed to identify clinical and biological markers associated with severe forms of COVID-19 in HD patients.

Methods: We conducted a prospective, observational and multicentric study.

[Estimation of urea distribution volume in hemodialysis patients].

Background: On-line urea clearance estimation, currently available on some dialysis monitors, makes it possible to calculate the dialysis dose Kt and thus allows to estimate Kt/V for each session, providing an estimation of urea distribution volume (V) at equilibrium assumed equal to total body water.

Methods: Three methods suitable for routinely estimating V, using the anthropometric Watson formula (V(Wat)), the body composition monitor (BCM) device (Fresenius Medical Care) based on bio-impedance analysis (V(imp)) and the indirect estimation (V(Daug)) obtained from measurement of Kt/(Kt/V)(sp) ratio respectively are compared during 25 dialysis sessions in 15 patients to a direct estimation (V(DDQ)) obtained by direct quantification of dialysis (DDQ) considered as the gold standard in hemodialysis patient..

MMP9 and SCF protect from apoptosis in acute kidney injury.

Apoptosis of tubular epithelial cells is a hallmark of acute kidney injury (AKI), but the cellular events preceding apoptosis in this setting are incompletely understood. Because matrix metalloproteinase 9 (MMP9) degrades matrix components involved in cell survival, we studied the role of MMP9 in AKI. In the mouse model of folic acid-induced AKI, we observed a marked increase of MMP9 activity in the S3 segment of the proximal tubule (S3PT), correlating with the apoptotic phase.

Costimulation blockade and its possible future use in clinical transplantation.

The nonimmune effects of currently used immunosuppressive drugs result in a high incidence of late graft loss due to nephrotoxicity and death of patients. As an immune-specific alternative to conventional immunosuppressants, new biotechnology tools can be used to block the costimulation signals of T-cell activation. Many experimental studies--particularly preclinical studies in nonhuman primates--have focused on blocking the 'classical' B7/CD28 and CD40/CD40L pathways, which are critical in primary T-cell activation.

Immunological strategies targeting B cells in organ grafting.

After delayed-type hypersensitivity and T cell cytotoxicity, the production of alloantibodies is the third effector mechanism contributing to graft injury. Histological characterization of antibody-mediated rejection and the detection of donor-reactive antibodies have highlighted the role of humoral immunity in acute and chronic rejection. A potential way of achieving central B cell tolerance is to induce complete chimerism with a myeloablative regimen and bone marrow transplant.